A randomized controlled trial on the effect of a known aldosterone blocker, spironolactone, on HF patients’ survival revealed the paramount impact on morbidity and mortality by lowering the atrial natriuretic peptide concentrations [43]. This evidence concerns the gene NPPA and hydrops fetalis.